News Releases

2013

Dec.24.2013 ONO Files for Regulatory Approval of "Nivolumab (ONO-4538/BMS-936558)" for Treatment of Malignant Melanoma(24.1KB)
Dec.16.2013 FDA Advisory Committee Recommends the Investigational SGLT2 Inhibitor Dapagliflozin for the Treatment of Type 2 Diabetes in Adults(423KB)
Dec.13.2013 Ono Establishes a Local Subsidiary in South Korea(63.3KB)
Dec.09.2013 Clinical Trial Application submitted for Phase I study of ONO-7268MX2, peptide-cocktail vaccine for hepatocellular carcinoma(86.9KB)
Dec.03.2013 AstraZeneca and Ono Enter Co-promotion Agreement in Japan for Dapagliflozin(94.3KB)
Nov.22.2013 Approval for Additional Indication of Onoact® 50 for injection, Short-Acting Selective β1 Blocker in Japan(117KB)
Nov.14.2013 Results of Phase II/III Study of ONO-2745/CNS 7056, a Short-acting General Anesthetic(89.8KB)
Nov.05.2013 Announcement on Financial Results for FY2013 2Q
Oct.28.2013 Fully Human Anti-PD-1 Antibody "Nivolumab (ONO-4538/BMS-936558)" Updated Results from a Phase 1 Study in Patients with NSCLC Presented at 15th World Conference on Lung Cancer(84.1KB)
Oct.22.2013 Ono Enters into License Agreement with Valeant(88.5KB)
Oct.09.2013 Ono Establishes a Local Subsidiary in South Korea(41.8KB)
Oct.01.2013 Fully Human Anti-PD-1 Antibody "Nivolumab (ONO-4538/BMS-936558)" Result from Phase II Study in Patients with Melanoma Presented at European Cancer Congress 2013(64.4KB)
Sep.27.2013 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced(57.6KB)
Sep.03.2013 Announcement on Annual Report 2013
Aug.27.2013 Rheumatoid Arthritis Drug ORENCIA® SC 125mg Syringe 1mL Launched in Japan(135KB)
Aug.13.2013 Ono Pharmaceutical and MSD applied for partial change in indications of "Sitagliptin", to add "type 2 diabetes"(45.9KB)
Aug.06.2013 Application Submission for Approval for the Stability-Improved Formulation of Limaprost,an Oral Prostaglandin E1 Analogue in Japan(28.0KB)
Aug.02.2013 Announcement on Financial Results for FY2013 1Q
Aug.02.2013 "Glactiv® tablets"for the oral treatment of type 2 diabetes Contraindication was removed and replaced by careful administration in patients with severe renal insufficiency(109KB)
July.05.2013 Subcutaneous (SC) formulation of ORENCIA® (abatacept) Results of Year Two Data from AMPLE Study in Patients with Moderate to Severe Rheumatoid Arthritis Presented at the European League Against Rheumatism (EULAR) Annual Congress(296KB)
Jun.28.2013 Rheumatoid Arthritis Drug ORENCIA® SC 125mg Syringe 1mL Approved for Production and Distribution(90.8KB)
Jun.04.2013 Bristol-Myers and Ono Pharmaceutical to Announce Lifting of Approval Conditions (Completion of PMS: "All-Case Surveillance") and Start of Co-Promotion(71.3KB)
Jun.03.2013 Fully Human Anti-PD-1 Antibody "ONO-4538/BMS-936558" Results from Phase 1 Study in Patients with Melanoma Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)(217KB)
May.16.2013 Detailed Results of Phase III Trial of L-BLP25 in Patients with Non-Small Cell Lung Cancer (START) to be Presented at ASCO(67.2KB)
May.13.2013 Voluntary adoption of International Financial Reporting Standards (IFRS)(134KB)
May.13.2013 Partial Amendment of Articles of Incorporation(16.9KB)
May.13.2013 Announcement on Financial Results for FY2012
May.09.2013 Announcement on Candidates of Members of the Board of Directors,Corporate Auditors and Corporate Officers(13.9KB)
May.08.2013 Ono and Dainippon Sumitomo reach agreement on expanding business relating to Limaprost into China(15.7KB)
Apr.18.2013 Ono Enters into License Agreement with Bial(9.8KB)
Feb.20.2013 Additional Indication Application filed for Onoact® 50 for injection,Short-Acting Selective β1 Blocker in Japan(80.1KB)
Feb.04.2013 Announcement on Financial Results for FY2012 3Q
Jan.25.2013 Discontinuation of Development for the Additional Indication of Carpal-Tunnel Syndrome, for Limaprost, an Oral Prostaglandin E1 Analogue(13.3KB)